NEW CONCEPTS

The New Concepts Symposium sponsored by Specialised Therapeutics Australia is designed as a novel way to reach out to a wider spectrum of the group. This session provides an opportunity for delegates to present embryonic new concepts for feedback and discussion with the audience as well as comments from international guests in terms of perspective, international interest and relevance.

A good idea can be tested and a perception gained on whether to take the concept forward to a more formal review by the Upper or Lower GI Working Party. The identification of other AGITG members who may wish to assist in progressing the concept as an AGITG supported protocol is also possible.

The winner of the Best New Concept Award will receive a $3,500 prize and a framed certificate. The runner up will receive a $1,500 prize and framed certificate both presented at the Annual Scientific Meeting Dinner. Details of the Best New Concepts Award are published on the AGITG website and in the Annual Report. Past winners have later been successful in submissions to the AGITG Innovation Fund which provides up to $200,000 for AGITG pilot research.

2018 New Concepts submissions are now closed.

Eligibility Criteria:

  • Fulfils the definition of translational or clinical research
  • International competitive science
  • Contribution to area of unmet need in Australia
  • Feasible as AGITG coordinated research
  • Fundable (contestable funding and/or charitable sources)

Process:

  • Concept submissions will be peer reviewed.
  • Four concepts will be chosen for presentation.
  • Selected concepts will be reviewed by a statistician with suggestions for improvement provided to the Investigator prior to printing the concept in the program book.
  • Following presentation of the concept a critique will be provided by the Invited International Faculty.
  • Delegates will then be invited to provide comments and the presenter will have opportunity to respond.
  • The process is intended to be constructive and result in refinement of the concept – with the aim of becoming an AGITG sponsored Protocol.
Best of New Concepts Awards 2017
Specialised Therapeutics Australia

2017 Sponsor

The Best of New Concepts Award is proudly sponsored by Specialised Therapeutics Australia.

2017 Winner Best of New Concepts ASM

2017 Winner – Best of New Concepts Award

Four concepts at the 2017 New Concepts Symposium. Congratulations to Dr Katherine Geddes of St Vincent’s’ Hospital VIC for winning the 2017 Best of New Concepts Award for her concept ‘The prevalence and significance of sarcopaenia in patients with operable adenocarcinoma of the stomach or gastro‐oesophageal junction undergoing treatment with curative intent and the impact of altered body composition on chemotherapy delivery’. Dr Geddes receives $3,500 and Best of New Concepts Award framed certificate.

2017 Runner Up – Best of New Concepts Award

2017 Runner Up – Best of New Concepts Award

The Co-Chairs of the New Concepts Symposium found the quality of the other three concepts presented to be of equal standing and awarded each a Runner-up Award of $500 and framed certificate.

Dr Andrew Dean of St John of God Hospital, Subiaco WA for his concept ‘Biliary neoplasm, OXaliplatin, Fluorouracil Folinic acid nal‐Irinotecan ChemothErapy for late / advanced tumours (BOXOFFICE)’.

Dr Andrew Oar of Liverpool Hospital NSW for his concept ‘A Feasibility Study using Mfolfirinox And STEreotactic Radiotherapy for Pancreatic cancer with Locally AdvaNced disease (MASTERPLAN)’.

Prof Phillip Clingan of the Illawarra Cancer Care Centre NSW for his concept ‘A Randomised, Multicentre, Open label Phase II Study of novel formulation Deflexifol in combination with Oxaliplatin (Delox) vs FOLFOX in subjects with unresectable metastatic colorectal cancer’.

Best of New Concepts Awards 2016
Specialised Therapeutics Australia

2016 Sponsor

The AGITG thanks Specialised Therapeutics Australia for sponsoring the Best of New Concepts Award.

Associate Professor Eva Segelov

2016 Winner – Best of New Concepts Award

Four concepts were presented at the 2016 New Concepts Symposium.

Congratulations go to Associate Professor Eva Segelov of St Vincent’s Hospital Sydney for winning the 2016 Best of New Concepts Award for her concept ‘Inducing immunogenicity in rectal cancer: A Phase I/II trial of aspirin +/- PD1 inhibitor in combination with neoadjuvant chemoradiation therapy for locally advanced rectal cancer: The INTIMACCI study (Inducing Tumour IMmunogenicity with Asprin, chemoradiation and Checkpoint Inhibition)’.

A/Prof Segelov receives $5,000 and Best of New Concepts Award framed certificate.

Best of New Concepts Awards 2015
Specialised Therapeutics Australia

2015 Sponsor

The AGITG thanks Specialised Therapeutics Australia for sponsoring the Best of New Concepts Award.

Prof Rob Ramsay, receiving his award for the New Concepts Symposium from Mr Luke Garrick and Ms Mary Rophael, Specialised Therapeutics Australia

2015 Winner – Best of New Concepts Award

The 2015 New Concepts Symposium featured six presentations of embryonic research concepts.

Prof Rob Ramsay from the Peter MacCallum Cancer Centre won the Best of New Concepts Award for his concept ‘Vaccination against Adenoid cystic and Colorectal Carcinoma Using MYB cDNA – VACCUMeD clinical trial – Immune Modulatory Therapy in Colorectal and Adenoid Cystic Carcinoma’.

A/Prof Barbara Mullan from Curtin University and Dr Haryana Dhillon from the University of Sydney were runners up with their concept ‘Managing bowel symptoms after colorectal cancer: an online dietary advice intervention’.

Best of New Concepts Awards 2014
Specialised Therapeutics Australia

2014 Sponsor

The AGITG thanks Specialised Therapeutics Australia for sponsoring the Best of New Concepts Award.

2014 Winner Best in New Concepts Dr Matthew Burge

2014 Winner – Best in New Concepts

The 2014 New Concepts Symposium featured seven presentations of embryonic research concepts.

Congratulations go to Dr Matthew Burge of Royal Brisbane Hospital for winning the Best of New Concepts Award for his concept ‘A randomised Phase 2/3 study of Infusional FU/LV with panitumumab V FU/LV/capecitabine with bevacizumab as first line therapy for never resectable, RAS and RAF wild type metastatic colorectal cancer’.

2014 Runner Up New Concepts

2014 Runner-Up – Best in New Concepts

Dr David Lau from the Ludwig Institute was awarded runner up for his concept entitled: “A phase II, single arm, multi-site study utilizing ctDNA to prospectively determine the evolution of cetuximab resistance prior to radiologic progression in metastatic colorectal cancer.”